CNS Pharmaceuticals (CNSP) Net Income (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Net Income came in at -$6.0 million in Q4 2025, down 87.13% YoY from -$46.5 million in Q4 2024, and down 83.96% on a QoQ basis from -$3.3 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Net Income (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Net Income data on file, last reported at -$6.0 million in Q4 2025.
- Quarterly Net Income fell 87.13% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16.0 million (down 7.28% YoY) and the FY2025 annual result came in at -$34.8 million, down 15.25% from the prior year.
- Net Income eased to -$6.0 million in Q4 2025, from -$3.3 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$2.4 million in Q2 2025 to a low of -$6.0 million in Q4 2025.
- A 5-year average of -$4.0 million and a median of -$3.7 million in 2021 frame the typical range for Net Income.
- Annual changes were most pronounced in 2021 — Net Income slumped 89.67% — and 2025, when it surged 42.19%.
- Tracing CNSP's Net Income over 5 years: stood at -$3.3 million in 2021, then plunged by 57.89% to -$5.1 million in 2022, then declined by 4.76% to -$5.4 million in 2023, then surged by 40.54% to -$3.2 million in 2024, then sank by 87.13% to -$6.0 million in 2025.
- The last three Net Income figures came in at -$6.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | CNS Pharmaceuticals | 2.66 Mn | -4.54 Mn | - | -5.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.99 Mn |
| Sep 30, 2025 | -3.26 Mn |
| Jun 30, 2025 | -2.41 Mn |
| Mar 31, 2025 | -4.34 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Sep 30, 2024 | -5.63 Mn |
| Jun 30, 2024 | -2.53 Mn |
| Mar 31, 2024 | -3.55 Mn |
| Dec 31, 2023 | -5.38 Mn |
| Sep 30, 2023 | -4.54 Mn |
| Jun 30, 2023 | -4.07 Mn |
| Mar 31, 2023 | -4.93 Mn |
| Dec 31, 2022 | -5.14 Mn |
| Sep 30, 2022 | -3.42 Mn |
| Jun 30, 2022 | -3.57 Mn |
| Mar 31, 2022 | -3.15 Mn |
| Dec 31, 2021 | -3.25 Mn |
| Sep 30, 2021 | -3.81 Mn |
| Jun 30, 2021 | -3.81 Mn |
| Mar 31, 2021 | -3.61 Mn |